Johnson & Johnson - JNJ Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Hold
Consensus Price Target: $175.86
Forecasted Upside: 19.78%
Number of Analysts: 13
Breakdown:
0 Sell Ratings
7 Hold Ratings
6 Buy Ratings
0 Strong Buy Ratings

^$146.82 As of 04/25/2024 01:00 AM ET

▼ -1.71 (-1.15%)

1 month | 3 months | 12 months

Get New Johnson & Johnson Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for JNJ and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for JNJ

^$175.86

▲ +19.78% Upside Potential

This price target is based on 13 analysts offering 12 month price targets for Johnson & Johnson in the last 3 months. The average price target is $175.86, with a high forecast of $215.00 and a low forecast of $162.00. The average price target represents a 19.78% upside from the last price of $146.82.

Current Consensus is Hold

The current consensus among 13 investment analysts is to hold stock in Johnson & Johnson. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
6 buy ratings
7 hold ratings
0 sell ratings

Ratings as of

11/2/2022

0 strong buy ratings
6 buy ratings
7 hold ratings
0 sell ratings

Ratings as of

1/31/2023

0 strong buy ratings
6 buy ratings
7 hold ratings
0 sell ratings

Ratings as of

5/1/2023

0 strong buy ratings
6 buy ratings
7 hold ratings
0 sell ratings

Ratings as of

7/30/2023

0 strong buy ratings
6 buy ratings
7 hold ratings
0 sell ratings

Ratings as of

10/28/2023

0 strong buy ratings
6 buy ratings
7 hold ratings
0 sell ratings

Ratings as of

1/26/2024

0 strong buy ratings
6 buy ratings
7 hold ratings
0 sell ratings

Ratings as of

3/26/2024

0 strong buy ratings
6 buy ratings
7 hold ratings
0 sell ratings

Ratings as of

4/25/2024

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/18/2024	HSBC	Upgrade	Hold ➝ Buy	$169.00 ➝ $170.00	Low
4/17/2024	Morgan Stanley	Lower Target	Equal Weight ➝ Equal Weight	$168.00 ➝ $167.00	Low
4/17/2024	Bank of America	Lower Target	Neutral ➝ Neutral	$180.00 ➝ $170.00	Low
4/17/2024	Royal Bank of Canada	Lower Target	Outperform ➝ Outperform	$181.00 ➝ $175.00	N/A
4/15/2024	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$215.00	Low
3/13/2024	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$215.00	Low
2/28/2024	Royal Bank of Canada	Reiterated Rating	Outperform ➝ Outperform	$181.00	Low
2/20/2024	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$215.00	Low
2/6/2024	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$215.00	Low
1/24/2024	Morgan Stanley	Lower Target	Equal Weight ➝ Equal Weight	$170.00 ➝ $169.00	Low
1/24/2024	Royal Bank of Canada	Reiterated Rating	Outperform ➝ Outperform	$181.00	Low
1/23/2024	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$215.00	Low
1/9/2024	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$215.00	Low
1/3/2024	Raymond James	Boost Target	Outperform ➝ Outperform	$172.00 ➝ $175.00	Low
12/18/2023	Cantor Fitzgerald	Reiterated Rating	Overweight		Low
12/13/2023	Wells Fargo & Company	Downgrade	Overweight ➝ Equal Weight	$170.00 ➝ $163.00	Low
12/1/2023	Royal Bank of Canada	Reiterated Rating	Outperform ➝ Outperform	$178.00	Low
12/1/2023	UBS Group	Upgrade	Neutral ➝ Buy	$167.00 ➝ $180.00	Low
11/17/2023	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$215.00	Low
10/18/2023	Morgan Stanley	Lower Target	Equal Weight ➝ Equal Weight	$174.00 ➝ $171.00	Low
10/18/2023	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$215.00	Low
10/18/2023	Raymond James	Lower Target	Outperform ➝ Outperform	$179.00 ➝ $172.00	Low
10/12/2023	Barclays	Boost Target	Equal Weight ➝ Equal Weight	$158.00 ➝ $162.00	Low
10/11/2023	Morgan Stanley	Boost Target	Equal Weight ➝ Equal Weight	$172.00 ➝ $174.00	Low
10/9/2023	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$215.00	Low
10/4/2023	Royal Bank of Canada	Initiated Coverage	Outperform	$178.00	Low
10/2/2023	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$215.00	Low
9/18/2023	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$215.00	Low
9/8/2023	Barclays	Lower Target	Equal Weight ➝ Equal Weight	$175.00 ➝ $158.00	Low
9/6/2023	HSBC	Initiated Coverage	Hold	$175.00	Low
9/5/2023	Raymond James	Lower Target	Outperform ➝ Outperform	$184.00 ➝ $179.00	Low
8/31/2023	Morgan Stanley	Lower Target	Equal Weight ➝ Equal Weight	$187.00 ➝ $172.00	Low
8/31/2023	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$215.00	Low
8/31/2023	Wells Fargo & Company	Lower Target	Overweight ➝ Overweight	$195.00 ➝ $186.00	Low
8/22/2023	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$215.00	Low
8/4/2023	Atlantic Securities	Boost Target	Neutral ➝ Neutral	$167.00 ➝ $170.00	Low
7/31/2023	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$215.00	Low
7/24/2023	Barclays	Boost Target	Equal Weight	$171.00 ➝ $175.00	Low
7/24/2023	Raymond James	Boost Target	Outperform	$181.00 ➝ $184.00	Low
7/21/2023	Morgan Stanley	Reiterated Rating	Equal Weight ➝ Equal Weight	$187.00	Low
7/21/2023	JPMorgan Chase & Co.	Boost Target	Neutral	$175.00 ➝ $180.00	Low
7/21/2023	Stifel Nicolaus	Boost Target		$165.00 ➝ $175.00	Low
7/21/2023	Credit Suisse Group	Boost Target	Neutral	$170.00 ➝ $175.00	Low
5/30/2023	Citigroup	Initiated Coverage	Buy	$185.00	Low
5/5/2023	Credit Suisse Group	Boost Target		$168.00 ➝ $170.00	Low
4/19/2023	Atlantic Securities	Lower Target	Neutral	$168.00 ➝ $167.00	Low
4/19/2023	Morgan Stanley	Boost Target	Equal Weight	$179.00 ➝ $183.00	Low
4/19/2023	Raymond James	Lower Target	Outperform	$185.00 ➝ $181.00	Low
4/10/2023	Morgan Stanley	Lower Target	Equal Weight	$180.00 ➝ $179.00	Low
3/28/2023	UBS Group	Initiated Coverage	Neutral	$164.00	Low
2/28/2023	Guggenheim	Initiated Coverage	Neutral	$161.00	Low
2/6/2023	Piper Sandler	Lower Target		$55.00 ➝ $52.00	Low
2/1/2023	Cantor Fitzgerald	Reiterated Rating	Overweight	$215.00	Low
1/25/2023	Atlantic Securities	Boost Target	Neutral	$160.00 ➝ $168.00	Low
1/25/2023	Morgan Stanley	Boost Target	Equal Weight	$176.00 ➝ $180.00	Low
1/20/2023	SVB Leerink	Lower Target	Outperform	$194.00 ➝ $186.00	Low
12/12/2022	Citigroup	Boost Target	Buy	$198.00 ➝ $205.00	Low
12/6/2022	Morgan Stanley	Lower Target	Equal Weight	$178.00 ➝ $176.00	Low
12/1/2022	Morgan Stanley	Boost Target		$170.00 ➝ $178.00	Low
11/17/2022	Credit Suisse Group	Initiated Coverage	Neutral	$170.00	Low
10/19/2022	Atlantic Securities	Lower Target	Neutral	$165.00 ➝ $160.00	Low
10/19/2022	Raymond James	Lower Target	Outperform	$192.00 ➝ $185.00	Low
10/19/2022	Morgan Stanley	Lower Target	Equal Weight	$174.00 ➝ $170.00	Low
10/19/2022	Sanford C. Bernstein	Lower Target		$194.00 ➝ $190.00	Low
10/17/2022	Barclays	Initiated Coverage	Equal Weight	$175.00	Low
10/14/2022	Bank of America	Lower Target	Neutral	$185.00 ➝ $178.00	Low
10/12/2022	Morgan Stanley	Boost Target	Equal Weight	$173.00 ➝ $174.00	Low
10/5/2022	Citigroup	Lower Target		$201.00 ➝ $198.00	Low
9/12/2022	Morgan Stanley	Lower Target	Equal Weight	$174.00 ➝ $173.00	Low
7/21/2022	UBS Group	Lower Target		$185.00 ➝ $180.00	Low
7/20/2022	SVB Leerink	Lower Target		$200.00 ➝ $194.00	Low
7/20/2022	Citigroup	Lower Target		$205.00 ➝ $201.00	Low
7/13/2022	Wells Fargo & Company	Boost Target	Overweight	$190.00 ➝ $195.00	N/A
7/8/2022	Morgan Stanley	Boost Target	Equal Weight	$173.00 ➝ $174.00	N/A
6/22/2022	Daiwa Capital Markets	Initiated Coverage	Outperform		Low
5/17/2022	Citigroup	Lower Target		$210.00 ➝ $205.00	N/A
4/20/2022	Raymond James	Boost Target	Outperform	$195.00 ➝ $196.00	Low
4/20/2022	Credit Suisse Group	Boost Target	Outperform	$200.00 ➝ $205.00	Low
4/20/2022	Citigroup	Boost Target	Buy	$203.00 ➝ $210.00	Low
4/14/2022	Raymond James	Boost Target	Outperform	$185.00 ➝ $195.00	Low
4/12/2022	The Goldman Sachs Group	Boost Target	Neutral	$163.00 ➝ $181.00	Low
4/6/2022	Morgan Stanley	Lower Target	Equal Weight	$175.00 ➝ $173.00	High
3/16/2022	Sanford C. Bernstein	Downgrade	Outperform ➝ Market Perform	$180.00 ➝ $183.00	Low
3/2/2022	Bank of America	Initiated Coverage	Neutral ➝ Neutral		Low
1/26/2022	Raymond James	Boost Target		$178.00 ➝ $185.00	Low
1/24/2022	Morgan Stanley	Lower Target	Equal Weight	$187.00 ➝ $175.00	Medium
12/17/2021	The Goldman Sachs Group	Initiated Coverage	Neutral	$161.00	High
12/15/2021	Citigroup	Reiterated Rating	Buy ➝ Buy	$192.00 ➝ $195.00	Low
10/20/2021	Raymond James	Lower Target	Outperform	$183.00 ➝ $178.00	Low
10/7/2021	Wells Fargo & Company	Reiterated Rating	Buy		Low
9/7/2021	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight	$187.00	Medium
7/29/2021	SVB Leerink	Reiterated Rating	Buy		Low
7/21/2021	SVB Leerink	Reiterated Rating	Outperform		Low
6/7/2021	Credit Suisse Group	Set Target	Buy	$193.00	Low
6/1/2021	Credit Suisse Group	Set Target	Buy	$193.00	High
5/28/2021	Morgan Stanley	Initiated Coverage	Overweight	$187.00	Low
1/27/2021	JPMorgan Chase & Co.	Boost Target	Neutral	$157.00 ➝ $175.00	Medium
1/27/2021	Credit Suisse Group	Boost Target	Outperform	$168.00 ➝ $193.00	Medium
1/27/2021	Raymond James	Boost Target	Outperform	$158.00 ➝ $183.00	Medium
1/27/2021	Cowen	Boost Target	Outperform	$170.00 ➝ $195.00	Medium
1/27/2021	Morgan Stanley	Boost Target	Overweight	$178.00 ➝ $187.00	Medium
1/27/2021	SVB Leerink	Boost Target	Outperform	$180.00 ➝ $200.00	Medium
1/27/2021	Wells Fargo & Company	Boost Target	Positive ➝ Overweight	$175.00 ➝ $190.00	Medium
1/26/2021	Cantor Fitzgerald	Boost Target	Positive ➝ Overweight	$180.00 ➝ $200.00	Medium
12/15/2020	Morgan Stanley	Boost Target	Overweight	$170.00 ➝ $178.00	Low
11/20/2020	Raymond James	Reiterated Rating	Buy		Medium
10/14/2020	Credit Suisse Group	Boost Target	Positive ➝ Outperform	$163.00 ➝ $168.00	Low
10/14/2020	Cantor Fitzgerald	Boost Target	Positive ➝ Overweight	$168.00 ➝ $180.00	Low
10/13/2020	Credit Suisse Group	Set Target	Buy	$163.00	Low
9/4/2020	Credit Suisse Group	Reiterated Rating	Buy		Medium
8/19/2020	Stifel Nicolaus	Downgrade	Buy ➝ Hold		Low
8/3/2020	Cantor Fitzgerald	Reiterated Rating	Buy	$168.00	Low
7/20/2020	Bank of America	Reiterated Rating	Buy		Low
7/20/2020	Independent Research	Upgrade	Hold ➝ Buy	$161.00 ➝ $164.00	Low
7/17/2020	Raymond James	Boost Target	Outperform	$157.00 ➝ $158.00	Medium
7/17/2020	Citigroup	Boost Target	Buy	$165.00 ➝ $170.00	Low
7/15/2020	SVB Leerink	Reiterated Rating	Outperform		Medium
4/29/2020	Morgan Stanley	Boost Target	Overweight	$160.00 ➝ $170.00	Low
4/29/2020	Barclays	Boost Target	Overweight	$173.00 ➝ $182.00	Low
4/28/2020	Cantor Fitzgerald	Reiterated Rating	Buy	$168.00	Low
4/28/2020	Credit Suisse Group	Reiterated Rating	Buy	$161.00	Low
4/28/2020	UBS Group	Downgrade	Buy ➝ Neutral	$163.00 ➝ $160.00	Medium
4/22/2020	Wells Fargo & Company	Upgrade	Hold		Medium
4/22/2020	Bank of America	Upgrade	Neutral ➝ Buy	$150.00 ➝ $175.00	Low
4/15/2020	Stifel Nicolaus	Boost Target	Hold	$140.00 ➝ $155.00	Medium
4/15/2020	Wells Fargo & Company	Boost Target	Overweight	$150.00 ➝ $162.00	Medium
4/15/2020	Citigroup	Boost Target	Buy	$150.00 ➝ $165.00	Medium
4/15/2020	Raymond James	Boost Target	Outperform	$153.00 ➝ $157.00	Low
4/15/2020	Credit Suisse Group	Boost Target	Outperform	$155.00 ➝ $161.00	Low
4/9/2020	Raymond James	Lower Target	Outperform	$161.00 ➝ $153.00	Low
4/8/2020	SVB Leerink	Lower Target	Outperform	$172.00 ➝ $160.00	High
4/3/2020	Cantor Fitzgerald	Reiterated Rating	Buy	$168.00	High
4/2/2020	Wells Fargo & Company	Lower Target	Overweight	$165.00 ➝ $150.00	Medium
4/1/2020	Stifel Nicolaus	Lower Target	Hold	$155.00 ➝ $140.00	Low
3/27/2020	Morgan Stanley	Lower Target	Overweight	$170.00 ➝ $160.00	Medium
3/27/2020	Citigroup	Lower Target	Buy	$163.00 ➝ $150.00	Low
3/27/2020	Argus	Reiterated Rating	Buy	$165.00 ➝ $155.00	Low
3/6/2020	Credit Suisse Group	Lower Target	Outperform	$170.00 ➝ $159.00	Medium
3/4/2020	Citigroup	Initiated Coverage	Buy	$163.00	Low
2/17/2020	Credit Suisse Group	Reiterated Rating	Buy	$170.00	Medium
1/27/2020	Credit Suisse Group	Boost Target	Outperform	$163.00 ➝ $170.00	Low
1/23/2020	Cantor Fitzgerald	Reiterated Rating	Buy	$168.00	Low
1/23/2020	Raymond James	Boost Target	Outperform	$147.00 ➝ $161.00	Low
1/9/2020	Wells Fargo & Company	Boost Target	Overweight	$155.00 ➝ $165.00	Low
12/31/2019	Credit Suisse Group	Reiterated Rating	Buy	$163.00	Low
12/19/2019	Barclays	Upgrade	Equal Weight ➝ Overweight	$140.00 ➝ $173.00	Medium
12/17/2019	Morgan Stanley	Upgrade	Equal Weight ➝ Overweight	$145.00 ➝ $170.00	Low
11/27/2019	Cantor Fitzgerald	Initiated Coverage	Overweight	$160.00	Low
11/19/2019	Cantor Fitzgerald	Initiated Coverage	Overweight	$160.00 ➝ $160.00	Low
10/24/2019	Credit Suisse Group	Boost Target		$158.00 ➝ $163.00	Low
10/16/2019	Credit Suisse Group	Boost Target	Outperform	$156.00 ➝ $158.00	Medium
10/16/2019	Wells Fargo & Company	Lower Target	Outperform	$157.00 ➝ $155.00	Medium
10/16/2019	Atlantic Securities	Upgrade	Underweight ➝ Neutral		Medium
10/14/2019	Raymond James	Lower Target	Outperform	$146.00 ➝ $145.00	Low
10/11/2019	Sanford C. Bernstein	Upgrade	Market Perform ➝ Outperform	$155.00	Low
8/27/2019	The Goldman Sachs Group	Set Target	Buy	$169.00	Medium
8/27/2019	Morgan Stanley	Reiterated Rating	Equal Weight	$145.00	High
8/27/2019	Credit Suisse Group	Set Target	Buy	$156.00	Low
7/18/2019	Credit Suisse Group	Set Target	Buy	$156.00	Low
7/17/2019	Raymond James	Lower Target	Outperform	$147.00 ➝ $146.00	Low
7/16/2019	Royal Bank of Canada	Reiterated Rating	Buy		Low
7/16/2019	Bank of America	Reiterated Rating	Hold	$150.00	Low
7/12/2019	Credit Suisse Group	Initiated Coverage	Outperform ➝ Outperform	$156.00	High
6/21/2019	Barclays	Initiated Coverage	Hold	$140.00	Low
5/28/2019	The Goldman Sachs Group	Initiated Coverage	Buy ➝ Buy		High
5/16/2019	Credit Suisse Group	Boost Target	Outperform	$152.00 ➝ $156.00	Low
5/6/2019	Wells Fargo & Company	Reiterated Rating	Outperform	$152.00 ➝ $157.00	Low

(Data available from 4/25/2019 forward)

News Sentiment Rating

0.44 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

39 very positive mentions
52 positive mentions
14 negative mentions
3 very negative mentions

Mentions as of

9/28/2023

48 very positive mentions
54 positive mentions
10 negative mentions
6 very negative mentions

Mentions as of

10/28/2023

18 very positive mentions
27 positive mentions
9 negative mentions
3 very negative mentions

Mentions as of

11/27/2023

59 very positive mentions
48 positive mentions
8 negative mentions
7 very negative mentions

Mentions as of

12/27/2023

62 very positive mentions
92 positive mentions
13 negative mentions
9 very negative mentions

Mentions as of

1/26/2024

72 very positive mentions
40 positive mentions
6 negative mentions
0 very negative mentions

Mentions as of

2/25/2024

69 very positive mentions
52 positive mentions
6 negative mentions
1 very negative mentions

Mentions as of

3/26/2024

91 very positive mentions
90 positive mentions
33 negative mentions
11 very negative mentions

Mentions as of

4/25/2024

Current Sentiment

Recent Stories by Sentiment

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.

Today's Range

Now: $146.82

$146.33

$149.58

50 Day Range

MA: $155.47

$144.45

$162.73

52 Week Range

Now: $146.82

$143.13

$175.97

Volume

7,591,467 shs

Average Volume

7,393,182 shs

Market Capitalization

$353.80 billion

P/E Ratio

9.15

Dividend Yield

3.18%

Beta

0.53

Frequently Asked Questions

What sell-side analysts currently cover shares of Johnson & Johnson?: The following Wall Street sell-side analysts have issued research reports on Johnson & Johnson in the last twelve months: Atlantic Securities, Bank of America Co., Barclays PLC, Cantor Fitzgerald, Citigroup Inc., Credit Suisse Group AG, HSBC Holdings plc, JPMorgan Chase & Co., Morgan Stanley, Raymond James, Royal Bank of Canada, Stifel Nicolaus, StockNews.com, TheStreet, UBS Group AG, and Wells Fargo & Company.
View the latest analyst ratings for JNJ.
What is the current price target for Johnson & Johnson?: 14 Wall Street analysts have set twelve-month price targets for Johnson & Johnson in the last year. Their average twelve-month price target is $175.86, suggesting a possible upside of 19.9%. Cantor Fitzgerald has the highest price target set, predicting JNJ will reach $215.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $162.00 for Johnson & Johnson in the next year.
View the latest price targets for JNJ.
What is the current consensus analyst rating for Johnson & Johnson?: Johnson & Johnson currently has 7 hold ratings and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in JNJ, but not buy more shares or sell existing shares.
View the latest ratings for JNJ.
What other companies compete with Johnson & Johnson?: Other companies that are similar to Johnson & Johnson include Merck & Co., Inc., AbbVie, Pfizer, Bristol-Myers Squibb and Eli Lilly and Company. Learn More about companies similar to Johnson & Johnson.
How do I contact Johnson & Johnson's investor relations team?: Johnson & Johnson's physical mailing address is ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ, 08933. The company's listed phone number is (732) 524-0400 and its investor relations email address is [email protected]. The official website for Johnson & Johnson is www.jnj.com. Learn More about contacing Johnson & Johnson investor relations.

Johnson & Johnson - JNJ Stock Price Target and Predictions

Analyst Price Target for JNJ

Current Consensus is Hold

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.44 (Hold)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Johnson & Johnson?

What is the current price target for Johnson & Johnson?

What is the current consensus analyst rating for Johnson & Johnson?

What other companies compete with Johnson & Johnson?

How do I contact Johnson & Johnson's investor relations team?